- Home
- Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This on-demand programme, Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice, has been developed to further education among practicing cardiologists to ensure understanding of the latest ARNI data in HFpEF and HFrEF, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of ARNI therapy in appropriate heart failure patients.
The programme brings together a leading international faculty from Malaysian, US, Germany, Singapore, for a four-part series, featuring eight videos.
This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.
Disclosure
In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.
This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.
Terms & Conditions
Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
This programme ‘Malaysia In Focus - ARNI Data And Its Implications On Clinical Practice’ is accredited by the Malaysian Medical Association (MMA) for 1 hour of external CPD credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Learning Objectives
- Understand the latest ARNI data in HFpEF and HFrEF
- Understand how emerging data relates to current practice in Malaysia
- Apply current understanding of ARNI therapy in appropriate heart failure patients
Meet the Expert Presentation – Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
Meet the Expert Q&A – Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore) Wan Azman Wan Ahmad (University of Malaya Medical Centre, Kuala Lumpur, Malaysia)
Interview – Managing Hypotension in Patients with HFrEF (Utilising ARNIs)
Duration:
Speakers: Carolyn Lam (National Heart Centre Singapore Duke-NUS, Singapore)
Clinical questions on ARNI therapy – Chapter 1: Local Interpretation of Emerging ARNI Data in HF
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Clinical questions on ARNI therapy – Chapter 2: ARNI Therapy Mode of Action
Duration:
Speakers: James L Januzzi (Massachusetts General Hospital, US) Akshay S Desai (Brigham and Women’s Hospital, Boston, MA, US) Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Clinical questions on ARNI therapy – Chapter 3: Safety and Efficacy of ARNI Therapy in Acute Heart Failure
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) David Morrow (Brigham and Women’s Hospital, US)
Clinical questions on ARNI therapy – Chapter 4: When to Initiate ARNI Therapy in Acute Heart Failure
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia) Rolf Wachter (University of Leipzig, Leipzig, Germany)
Clinical questions on ARNI therapy – Chapter 5: Summary
Duration:
Speakers: Azmee Mohd Ghazi (National Heart Institute, Kuala Lumpur, Malaysia)
Related Courses
- Not accredited
Published:
Learning objectives
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- Not accredited
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF